193 related articles for article (PubMed ID: 1565635)
1. Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum.
Maki T; Ichikawa T; Blanco R; Porter J
Proc Natl Acad Sci U S A; 1992 Apr; 89(8):3434-8. PubMed ID: 1565635
[TBL] [Abstract][Full Text] [Related]
2. Effect of STZ administration on islet isograft and allograft survival in NOD mice.
Takayama Y; Ichikawa T; Maki T
Diabetes; 1993 Feb; 42(2):324-9. PubMed ID: 8425668
[TBL] [Abstract][Full Text] [Related]
3. Depleting anti-CD4 monoclonal antibody cures new-onset diabetes, prevents recurrent autoimmune diabetes, and delays allograft rejection in nonobese diabetic mice.
Makhlouf L; Grey ST; Dong V; Csizmadia E; Arvelo MB; Auchincloss H; Ferran C; Sayegh MH
Transplantation; 2004 Apr; 77(7):990-7. PubMed ID: 15087759
[TBL] [Abstract][Full Text] [Related]
4. Combination of anti-CD4 with anti-LFA-1 and anti-CD154 monoclonal antibodies promotes long-term survival and function of neonatal porcine islet xenografts in spontaneously diabetic NOD mice.
Arefanian H; Tredget EB; Rajotte RV; Korbutt GS; Gill RG; Rayat GR
Cell Transplant; 2007; 16(8):787-98. PubMed ID: 18087999
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy with nondepleting anti-CD4 monoclonal antibodies but not CD28 antagonists protects islet graft in spontaneously diabetic nod mice from autoimmune destruction and allogeneic and xenogeneic graft rejection.
Guo Z; Wu T; Kirchhof N; Mital D; Williams JW; Azuma M; Sutherland DE; Hering BJ
Transplantation; 2001 Jun; 71(11):1656-65. PubMed ID: 11435979
[TBL] [Abstract][Full Text] [Related]
6. Nondepleting anti-CD4 and soluble interleukin-1 receptor prevent autoimmune destruction of syngeneic islet grafts in diabetic NOD mice.
Drage M; Zaccone P; Phillips JM; Nicoletti F; Dawson J; Andrew Bradley J; Cooke A
Transplantation; 2002 Sep; 74(5):611-9. PubMed ID: 12352875
[TBL] [Abstract][Full Text] [Related]
7. Long-term survival of segmental pancreas isografts in NOD/Lt mice treated with anti-CD4 and anti-CD8 monoclonal antibodies.
Mottram PL; Murray-Segal LJ; Han W; Maguire J; Stein-Oakley A; Mandel TE
Diabetes; 1998 Sep; 47(9):1399-405. PubMed ID: 9726227
[TBL] [Abstract][Full Text] [Related]
8. Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4.
Ogawa N; List JF; Habener JF; Maki T
Diabetes; 2004 Jul; 53(7):1700-5. PubMed ID: 15220193
[TBL] [Abstract][Full Text] [Related]
9. CD8 T cells are not required for islet destruction induced by a CD4+ islet-specific T-cell clone.
Bradley BJ; Haskins K; La Rosa FG; Lafferty KJ
Diabetes; 1992 Dec; 41(12):1603-8. PubMed ID: 1446802
[TBL] [Abstract][Full Text] [Related]
10. Abrogation of recurrent autoimmunity in the NOD mouse: A critical role for host interleukin 4.
Shi Q; Wang D; Hadley GA; Farber DL; Bartlett ST
Surgery; 2006 Aug; 140(2):281-8. PubMed ID: 16904981
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppressive antibody treatment prolongs graft survival in two murine models of segmental pancreas transplantation.
Purcell LJ; Mottram PL; Mandel TE
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():349-52. PubMed ID: 8225401
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.
Chatenoud L; Thervet E; Primo J; Bach JF
Proc Natl Acad Sci U S A; 1994 Jan; 91(1):123-7. PubMed ID: 8278351
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune destruction of islet grafts in the NOD mouse is resistant to 15-deoxyspergualin but sensitive to anti-CD4 antibody.
Stegall MD; Loberman Z; Ostrowska A; Coulombe M; Gill RG
J Surg Res; 1996 Aug; 64(2):156-60. PubMed ID: 8812627
[TBL] [Abstract][Full Text] [Related]
14. Remission and pancreas isograft survival in recent onset diabetic NOD mice after treatment with low-dose anti-CD3 monoclonal antibodies.
Mottram PL; Murray-Segal LJ; Han W; Maguire J; Stein-Oakley AN
Transpl Immunol; 2002 Jun; 10(1):63-72. PubMed ID: 12182467
[TBL] [Abstract][Full Text] [Related]
15. Anti-TCR mAb induces peripheral tolerance to alloantigens and delays islet allograft rejection in autoimmune diabetic NOD mice.
Deng R; Khattar M; Xie A; Schroder PM; He X; Chen W; Stepkowski SM
Transplantation; 2014 Jun; 97(12):1216-24. PubMed ID: 24854475
[TBL] [Abstract][Full Text] [Related]
16. Endogenous expansion of regulatory T cells leads to long-term islet graft survival in diabetic NOD mice.
Shi Q; Lees JR; Scott DW; Farber DL; Bartlett ST
Am J Transplant; 2012 May; 12(5):1124-32. PubMed ID: 22299822
[TBL] [Abstract][Full Text] [Related]
17. Prevention of autoimmune but not allogeneic destruction of grafted islets by different therapeutic strategies.
Kuttler B; Rösing K; Lehmann M; Brock J; Hahn HJ
J Mol Med (Berl); 1999 Jan; 77(1):226-9. PubMed ID: 9930969
[TBL] [Abstract][Full Text] [Related]
18. Differential outcomes in prediabetic vs. overtly diabetic NOD mice nonmyeloablatively conditioned with costimulatory blockade.
Bozulic LD; Huang Y; Xu H; Wen Y; Ildstad ST
Exp Hematol; 2011 Oct; 39(10):977-85. PubMed ID: 21726515
[TBL] [Abstract][Full Text] [Related]
19. Prevention of recurrence of IDDM in islet-transplanted diabetic NOD mice by adjuvant immunotherapy.
Wang T; Singh B; Warnock GL; Rajotte RV
Diabetes; 1992 Jan; 41(1):114-7. PubMed ID: 1727730
[TBL] [Abstract][Full Text] [Related]
20. Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, rapamycin, and anti-interleukin-2 antibody.
Molano RD; Pileggi A; Berney T; Poggioli R; Zahr E; Oliver R; Malek TR; Ricordi C; Inverardi L
Transplantation; 2003 Jun; 75(11):1812-9. PubMed ID: 12811239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
